StockData
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31

PERRIGO Co plc

Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$16.09−0.54 (-3.25%)

Close on Oct 19, 2026

Market cap
$2.25B
P/E (TTM)
–
Dividend yield
7.21%

About Perrigo

Pharmaceutical Preparations, SIC 2834

Perrigo Company plc provides over-the-counter self-care, health, and wellness products. The company operates through two business segments: Consumer Self-Care Americas and Consumer Self-Care International. Its product portfolio spans upper respiratory remedies, infant nutrition, digestive health, pain and sleep aids, oral hygiene, skincare, women's health, and dietary supplements. Perrigo produces retailer store brands as well as proprietary branded goods. Its customers include retail pharmacies, supermarkets, mass merchants, wholesalers, and e-commerce platforms, with Walmart serving as its largest individual customer.

The company employs roughly 8,100 people across 31 countries and markets products in more than 30 countries, predominantly in North America and Europe. Its primary manufacturing operations reside in the United States, supplemented by production facilities in the United Kingdom, Belgium, France, Germany, and China, as well as distribution hubs across the United States, Europe, and Australia. Perrigo is incorporated under Irish law, while a specific headquarters location is not identified in the text.

Summary of the business section of Perrigo's latest annual report, written by StockData.

Company profile

Company

Legal name
PERRIGO Co plc
Founded
1887
Headquarters
Dublin 2, L2
Address
The Sharp Building, Hogan Place D02 TY74
Phone
(269) 673-8451
Employees
8,100, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
L2
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Grand Rapids, Michigan

Stock & identifiers

Ticker
PRGO
Exchange
NYSE
IPO date
Dec 17, 1991
Shares outstanding
139M, Jul 31, 2026
Public float
$3.65B, Jun 27, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Aug 26, 1993
SEC CIK
1585364
CUSIP
G97822103
ISIN
USG978221038
LEI
549300IFOQS6R1QLY196
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Albert ManzoneInterim President and CEO, Director16,353
David BallEVP & CBDO11,664
Eduardo Guarita BezerraEVP & Chief Financial Officer84,700
Roberto KhouryEVP and President of CSCI14,113
Matthew John WintermanEVP, Supply, Ops, Strategy8,365
Charles AtkinsonEVP, General Counsel & Sec.5,855
Abigail LennoxEVP and CSO4,607
Robert WillisEVP & CHRO50,568
Triona SchmelterEVP & President CSCA6,670
Ronald Craig JanishEVP, Gbl Ops & SC & CTO40,574
Bradley A. AlfordDirector46,728
Geoffrey M. ParkerDirector77,734
Ahmed Salman AminDirector0
Muhammad Omer GajialDirector0
Jonas SamuelsonDirector1,594
Kevin Francis EganDirector3,798
Orlando D. AshfordDirector27,717
Donal O'ConnorDirector39,140
Julia M. BrownDirector15,339
Adriana KaraboutisDirector27,629
Jeffrey B. KindlerDirector10,559

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
P.Lockwood Taylor
$9.04M$2.86M$3.49M$37$141
FY2024$7.14M$4.95M$2.63M$65$137
FY2024
Current Ceo
$7.14M$4.95M$2.63M$65$137
FY2024
Former Ceo
$0$0$2.63M$65$137
FY2024
P.Lockwood Taylor
$7.14M$4.95M$2.63M$65$137
FY2023
Current Ceo
$6.07M$5.91M$2.51M$78$119

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“Our global workforce consists of approximately 8,100 full-time and part-time employees spread across 31 countries, of which approximately 17.5% were covered by collective agreements as of December 31, 2025.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 30, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 16, 2024DelistingNotice of delisting from exchange (Form 25)
Oct 7, 2024ListingRegistration of securities on an exchange (Form 8-A)
Oct 2, 2024DelistingNotice of delisting from exchange (Form 25)
Jul 15, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 20, 2022DelistingNotice of delisting from exchange (Form 25)
May 2, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 12, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 6, 2020DelistingNotice of delisting from exchange (Form 25)
May 11, 2017Late filingNotification of late filing
May 9, 2017DelistingNotice of delisting from exchange (Form 25)
Mar 29, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 17, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 27, 2017Late filingNotification of late filing
Nov 16, 2016ListingRegistration of securities on an exchange (Form 8-A)
May 13, 2016Late filingNotification of late filing
Sep 14, 2015Tender offerThird-party tender offer for the company's shares
Mar 30, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 15, 2014MergerRegistration of securities for a merger or exchange offer (S-4)
Jan 31, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 19, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 12, 2013Name changeName changed from PERRIGO Co Ltd to PERRIGO Co plc
Aug 28, 2013MergerRegistration of securities for a merger or exchange offer (S-4)